Full text is available at the source.
Abstract
Incretin-based therapies are evaluated as cardiometabolic interventions across multiple health conditions.
- Initially developed for improving insulin secretion and blood sugar control in type 2 diabetes.
- Clinical interpretations have broadened to include effects on cardiovascular health and kidney function.
- Evidence from various studies suggests potential benefits in managing obesity alongside diabetes.
- Outcomes from cardiovascular and kidney trials indicate these therapies may influence broader metabolic health.
Simplified